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1. ABSTRACT 
 Pain is the first sign of malignancy and prevalent symptom experienced by cancer patients. 
Circadian rhythm is the best known and probably most general rhythm in living creatures. It 
plays a very important role in the pattern of pain produced by various diseases.  Time dependent 
variation affects perception of pain, its neurochemistry, and drug treatment. Endogenous insulin 
plays a critical role in the modulation of pain has been documented in clinical and preclinical 
studies. The aim of this study was to determine the insulin’s antinociceptive effect and also to 
study the influence of circadian rhythm on cancer pain. This study was done in Erode Cancer 
centre, Erode wherein we recruited 22 patients for the study. Patients were categorized as Group 
A, Group B, Group C.  Group A included patients taking opiod drugs,  Group B-patient taking 
nonopiods and Group C control patients without pain. Pain was assessed in patients using Visual 
Analogue Scale. Blood samples were collected from patients four times a day (6AM, 12PM, 
6PM, 12AM)with their consent. Serum Insulin level were determined by ELISA method using 
DRG INSULIN KIT. Results were analyzed using computerized statistical package of Graphpad 
Instat Software. The statistical significance was tested by the analysis of variance(ANOVA)  and 
Tukey - Kramer Multiple Comparisons Test.  In opioid taking patients serum insulin level 
showed a increase in morning 6AM(31.3125±20.812 ) and afternoon 12PM (33.05±12.757). 
Whereas in nonopioid taking group increase in insulin level was  found at evening 6PM 
(69.1875±21.290) and midnight 12AM(67.337±30.728). The serum insulin level in opioid and 
nonopioiod taking patients was increased and found highly significant(p value<0.0001) than 
control group although no significant differences in mean values of blood glucose were observed   
. In this study it was found that  endogenous insulin play an important role in the modulation of 
pain in cancer pain and also circadian rhythm influences cancer pain 
.  
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2.   INTRODUCTION 
Pain is an unpleasant sensation of hurt which signals current or impending tissue damage 
or a pattern of responses which operate to protect the organism from harm1. It is a complex 
experience and is highly subjective2. There are both acute and chronic painful conditions. 
Cancer known medically as a malignant neoplasm, is a large group of different diseases, all 
involving unregulated cell growth. In cancer, cells divide and grow uncontrollably, forming 
malignant tumors, and invade nearby parts of the body. The cancer may also spread to other 
distant parts of the body through the lymphatic system or bloodstream. Not all tumors are 
cancerous. Benign tumors do not grow uncontrollably, do not invade neighboring tissues, and do 
not spread throughout the body3. 
Pain in cancer values priority because of many perspectives. In cancer patients, pain can affect 
the patient’s quality of life and may in turn affect the patient’s will to live or to cooperate in 
treatment. Pain is the first sign of malignancy and prevalent symptom experienced by cancer 
patients6. Pain further worsens already debilitated cancer patients condition7 .  
An estimated 6.6 million people from around the world die from cancer each year10. In the early 
diagnosis of disease, 30-50% of cancer patients experience pain while 70- 90 % of advance state 
cancer patients experience pain. When diagnosed 60-80% of patients, are diagnosed as advanced 
cases11. In cancer, pain can occur at any point during the course of the illness. Cancer pain 
depends on the type and stage of disease. Also pain in cancer can be due to the pain caused by 
cancer itself, by cancer treatment such as surgery, radiation, or chemotherapy, or by the side 
effects of treatment. 
Pain management in cancer pain includes analgesics, surgery, nerve blocks, anticancer therapies 
and psychological techniques12. But often cancer pain remains prevalent and undertreated14. 
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However pain remains a serious medical issue and   pain control or pain relief remains a 
insignificant health care matter15. 
 Various chemical mediators such as prostaglandins, bradykinin, 5-Hydroxytryptamine(5-HT), 
opioid and nonopioid peptides, enkephalins, β-endorphin and substance P, neurokinin-A, 
neurokinin-B, neurotensin, and cytokines are involved in pain 16. 5-HT, bradykinins, opioid 
peptides, Ach, GABA(Gamma amino butyric acid) are chemical agents involved in the activation 
of nociceptors2. 
 Insulin is a hormone regulating carbohydrate and fat metabolism in the body. It has been 
postulated in many studies that insulin has got antinociceptive action. The influence of morphine 
and ibuprofen on endogenous insulin in patients with cancer pain showed insulin’s 
antinociceptive activity by a significant increase in serum insulin values17. 
Antinociceptive response was potentiated in mice due to the administration of insulin 
exogenously. The analgesic effect of insulin was mediated by 5-hydroxtryptamine, dopamine, 
NMDA (N-methyl-D-aspartate), opioidergic receptors and potassium and calcium channels18. 
Insulin showed antinociceptive activity without any hypoglycemic action when administered 
intra cerebroventricularly.Insulin modulated chronic pain rather than acute pain through some 
central mechanism mediated by dopamine,5-hydroxytryptamine and opioids.Release of 
endogenous opioids contribute to insulin’s antinociceptive action19. Insulin increased the 
analgesic action of sodium salicylates20.   
Insulin is implicated in the modulation of pain threshold. Formalin induced pain was attenuated 
by insulin19. Another preclinical study revealed that antinociception was potentiated with 
flavones in mice, endogenous insulin level was significantly increased. This study also stated 
that there exists no relationship between glycemic state in acute painful condition and 
antinociceptive response. Insulin is involved in the modulation of pain in animals21. Exogenous 
administration of insulin induced hypoglycemia which ultimately raised the antinociceptive 
action of morphine in rats by the tail flick test22. Insulin may also function as a neuro 
modulator18. 
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Circadian rhythm is the best known and probably most general rhythm in living creatures. It 
plays a very important role in the pattern of pain produced by various diseases. The pattern of 
pain observed in each clinical state is specific2. Cancer pain shows peak at 6pm and trough hours 
at 4-10 am15 .Many studies reports time dependent variation in the perception of pain, its 
neurochemistry, and on drug treatment. Circadian variation in pain intensity could be the best 
marker to use in determining when analgesics should be administered. Pain treatment still 
remains inadequate because not enough attention has been given to time-of-day patterns of pain 
intensity2 .Various mediators and hormones are released based on circadian rhythm. Insulin is a 
hormone and release of insulin in the body is based up on the circadian rhythm23. 
The above literatures signals that that hormone levels are influenced and released based on 
circadian rhythm. From further literatures it is clearly understood that there exists a relationship 
between insulin in painful condition, but insulin’s role and mechanism in the modulation of pain 
is not clearly understood. However, this study was directed towards identifying the role of 
circadian rhythm on  serum insulin level and blood glucose level and insulin’s role in the 
modulation of pain. 
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3. REVIEW OF LITERATURE 
 3.1 PAIN: 
One of the commonest symptom for which a person approaches medical care is pain. The 
International Association for the Study of Pain defines pain as “An unpleasant sensory and 
emotional experience arising from actual or potential tissue damage or described in terms of such 
damage”1. 
The American Academy of Pain Medicine defines pain as – “An unpleasant sensation and 
emotional response to that sensation”1.  
The Web version of the Encyclopedia Britannica defines pain as – “A complex experience 
consisting of a physiological (bodily) response to a noxious stimulus followed by an affective 
(emotional) response to that event. Pain is a warning mechanism that helps to protect an 
organism by influencing it to withdraw from harmful stimuli. It is primarily associated with 
injury or the threat of injury, to bodily tissues” 1.  
Pain is a very complex phenomenon, characterized as an unpleasant sensation that diminishes 
person’s normal patterns of patient’s activity, sleep, appetite and thoughts. It is highly subjective, 
and factors such as anxiety, fatigue, suggestion, or emotion, as well as prior experiences can 
influence its perception2. 
3.2 TYPES OF PAIN: 
Pain is of two types, acute and chronic. 
ACUTE PAIN: 
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 Acute pain is generally a signal of rapid-onset injury to the body, and it resolves when pain 
relief is given and/or the injury is treated. The cause is well defined. It may be due to illness, 
trauma, surgery or any painful medical procedures. Acute pain can sometimes be beneficial to 
patient in diagnosing a disease and treating it. The primary goal of acute pain treatment is to 
diagnose the source and remove it1. 
 
CHRONIC PAIN: 
Pain is considered chronic when it lasts beyond the normal time expected for an injury to heal or 
an illness to resolve. Chronic pain, sometimes called persistent pain, can be very stressful for 
both the body and the soul. Chronic pain is pain that has outlived its usefulness and is no longer 
beneficial to the patient. The main goals of chronic pain treatment are to minimize the pain, limit 
disability and to improve person’s functioning. Complete relief of pain is rare in chronic pain. 
The more realistic goal is to decrease the level of pain to a tolerable level that allows the person 
to focus on everyday activities1. 
3.3 CANCER: 
Cancer is a disease characterized by uncontrolled multiplication and spread of abnormal forms 
of the body's own cells. It is one of the major causes of death in the developed nations: The terms 
cancer, malignant neoplasm (neoplasm simply means 'new growth') and malignant tumor are 
synonymous. Both benign and malignant tumors manifest uncontrolled proliferation, but the 
latter are distinguished by their capacity for dedifferentiation, their invasiveness and their ability 
to metastasize24. 
3.4 CANCER PAIN: 
Pain in cancer can be devastating. Pain in cancer is of great significance because it causes 
physical, psychosocial & psychological distress to the unfortunate victim, considerably 
damaging their personal and social lives25. 
3.5 TYPES OF CANCER PAIN: 
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Temporal categories of cancer pain include: 
ACUTE PAIN: 
• Related to a specific event (surgery, injury). 
• Short lasting, as recover from the surgery, the pain at the incision goes away. 
• Need for taking pain medicine is short. Pain disappears by taking strong medicine (a 
narcotic) to less strong medicine to no need for  taking pain medicine 
CHRONIC PAIN: 
• Can last months to years even if cause of pain has healed (surgery) or been removed 
(chemo done). 
• If untreated, pain signals continue and becomes remembered (feelings of pain continue) 
in your brain even after the pain is gone. 
• This is real pain and is not just in mind. 
• Affects sense of well-being and quality of life. 
• Requires the use of pain medicine(s) for longer periods of time, possibly the rest of your 
life. 
PHANTOM (LIMB) PAIN:  
• Feeling that the limb or breast is still there even after it has been removed. 
• Pain that may ache, throb or otherwise give an unpleasant or hurting feeling. 
• The pain is real. 
BREAKTHROUGH PAIN:  
• Unexpected pain that occurs between doses of pain medicine (called a pain flare). 
• Pain gets very bad in 3-5 minutes. 
• Pain flares may last about 30 minutes. 
• Each time pain flares are not same. 
• Usually treated with a pain medicine that acts very quickly and doesn’t last for long. 
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• Usually means pain medicine needs to be adjusted (may need more medicine) 
PAIN FLARES can be caused by: 
• Doing something like moving, gardening. 
• Pain medicine does not last as long or relieves pain as it should. 
• Sometimes there is no obvious cause; the pain flare just happens. 
Physiologic categories of cancer pain include: 
 NEUROPATHIC PAIN (INVOLVES NERVE ENDINGS): NERVE DAMAGE BY 
TUMOR OR CANCER TREATMENT:  
• The nerve is injured or squeezed by the cancer or cancer treatment. 
• Pain may be felt as burning, shooting, stabbing, or numbness. Some say it feels like pins 
and needles.  
• Sometimes called peripheral neuropathy 
NOCICEPTIVE PAIN: 
• Pain arising from damage to tissues other than nerve fibers. It is also called tissue pain. 
The undamaged nerve cells called nociceptors carry the sensation to spinal cord from 
where it is relayed to the brain. It is called somatic pain if it results from injury to 
muscles, tendons and ligaments. 
•  Somatic pain is usually well localized. It is called visceral pain if it results from injury to 
the internal organs like stomach, gall bladder and urinary bladder. Visceral pain is usually 
diffuse and non-localizing. 
• Somatic pain in turn is classified in to cutaneous somatic pain if the pain arises from the 
skin   and deep somatic pain if it is from deeper musculoskeletal tissues. The various 
causes of joint pain are grouped under musculoskeletal pain. 
 
3.6 EPIDEMIOLOGY: 
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An estimated 6.6 million people from around the world die from cancer each year10. In the early 
diagnosis of disease, 30-50% of cancer patients experience pain while 70- 90 % of advance state 
cancer patients experience pain. When diagnosed 60-80% of patients, are diagnosed as advanced 
cases11. 
Cancer prevalence in India is estimated to be around 2.5 million, with over 8, 00,000 new cases 
and 5, 50,000 deaths occurring each year. 
3.7 AETIOLOGY OF CANCER PAIN: 
Not everyone who has cancer has pain. For those who do have pain, there are many different 
causes: 
CANCER ITSELF: 
The cancer itself causes about 65%-80% of cancer pain 
• Pressure of the tumor on an organ (liver, lungs), bone or nerves 
• Cancer growth into bone, nerves or an organ 
• Sometimes cancer can cause pain when blood vessels become obstructed by the tumor. 
CANCER TREATMENTS: 
The cancer treatments cause about 15%-25% of pain 
• Chemotherapy 
o Mouth sores 
o Numb fingers, feet 
o Bone or joint pain 
• Surgery 
o Cutting across a nerve during surgery 
o Pain from incision 
• Radiation therapy 
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o Nerve ending sensitivity 
o Skin irritation 
o Procedures for treatment, evaluation or diagnosis (cause about 5%-10% of pain) 
• Biopsy (cutting out the cancer or a a piece of the cancer to make a diagnosis) 
• Blood draws (using a needle to remove blood from a vein) 
• Placing a needle into the spine area (back bone) to give medication (called a lumbar 
puncture) also could be used to give pain medication 
• lumbar punctures, laser treatments, bone marrow tests etc. can cause pain 
•  Not related to cancer or cancer treatment 
 Other diseases (diabetes, heart problems, arthritis) 
 Injury (car accidents) 
 
     THE DIFFERENT CAUSES FOR PAIN IN PEOPLE WITH CANCER: 
• Physical from the cancer or the treatment 
• Intellectual - knowledge, memory loss, self-control, review of life issues 
o Emotional pain anxiety, fear, grief 
o Interpersonal pain burden, physical needs, overprotection 
o Financial pain costs, loss of job 
o Spiritual pain facing death, questions of faith, feelings 
o Bureaucratic pain - more doctors, tests, questions25 
 
3.8 PATHOPHYSIOLOGY:  
Pain is initiated by stimulation of nociceptors in the peripheral nervous system, or by damage to 
or malfunction of the peripheral or central nervous systems .A nociceptor is a sensory receptor 
that reacts to potentially damaging stimuli by sending nerve signals to the spinal cord and brain. 
This process, called nociception, usually causes the perception of pain. In mammals, nociceptors 
are sensory neurons that are found in any area of the body that can sense pain either externally or 
internally. Nociceptors neuron sensitivity is modulated by a large variety of mediators in the 
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extracellular space. Peripheral sensitization represents a form of functional plasticity of the 
nociceptors.  
 
 
 
 
BASIC PROCESS OF NOCICEPTIVE PAIN TRANSMISSION: 
  
STIMULATION-Noxious stimulus sensitizes and/or stimulates nociceptors and causes the 
release of neural chemicals that also sensitize and/or stimulate nociceptors. This activation leads 
to the production of an action potential. 
 
TRANSMISSION- The action potential continues from the site of noxious stimulus to the 
dorsal horn of the spinal cord and then ascends to higher centres in the CNS. Transmission takes 
place in atleast five pathways: 
a.Spinothalamic tract 
b.Sspinoreticular tract 
c.Spinomesencephalic tract 
d.Dorsal column postsynaptic spinomedullary pathway 
e.Propriospinal multisynaptic ascending systems 
 
PERCERPTION-Conscious experience of pain 
 
MODULATION-Inhibition of nociceptive impulses. Neurons from the brain stem descend to 
the spinal cord and release substances such as endogenous opioids, serotonin, and nor 
epinephrine that inhibit transmission of nociceptive impulses27. 
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Fig 1. Schematic representation of Pain Pathway. 
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Fig.2 Ascending and Descending Pain Pathway. 
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     3.9 SIGNS AND SYMPTOMS OF CANCER PAIN: 
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• Acute pain 
• Chronic pain 
• Superficial pain 
• Visceral pain is usually diffuse and non-localizing. 
• Somatic pain is usually, dull, aching, usually well localized pain. Somatic pain in turn is 
classified in to cutaneous somatic pain if the pain arises from the skin and deep somatic 
pain if it is from deeper musculoskeletal tissues. The various causes of joint pain are 
grouped under musculoskeletal pain. 
• Neuropathic pain is the pain caused by lesion in the nervous system when they are 
structurally or functionally damaged. It is called central pain if the lesion is the central 
nervous system. It is called peripheral neuropathic pain if the lesion is in the peripheral 
nervous system. The neuropathic pain is described as severe, sharp, lancinating, 
lightning-like, stabbing, burning, cold, numbness, tingling or weakness. It may be felt 
traveling along the nerve path from the spine down to the arms/hands or legs/feet25.  
 
3.10 DIAGNOSIS OF CANCER PAIN USING PAIN ASSESMENT SCALES: 
 
The most commonly used scales are visual analogue and verbal rating scale. Visual analogue 
scales are lines 10 cm long with the extremes at each end labeled usually “no pain at all” and 
“worst pain imaginable” respectively. The patient is required to mark the severity of the pain 
between the two extremes of the scale. Verbal rating scales use adjectival descriptors such as 
‘none’, ‘mild’, moderate and excruciating. More elaborate questionnaires such as the McGill 
pain questionnaire helps to describe other aspects of the pain and pain diaries record the 
influence of activity and medication on pain26.  
 
 
16 
 
3.11 CANCER PAIN MANAGEMENT: 
Cancer pain management aims at ensuring the quality of life in cancer patients. Pain in cancer 
has been conceptualized as a multidimensional phenomenon, which needs multidisciplinary care. 
In cancer pain, drug treatment is the mainstay of pain management. Between 70% and 90% of all 
cancer pain can be controlled with oral medication. Adequate pain relief can be achieved in more 
than 75% of patients who receive optimal analgesic management using simple techniques such 
as opioids, non-opioid analgesics, and adjuvant medications, as suggested by the World Health 
Organization’s analgesic ladder. It is recommended that drugs should be given by mouth, by the 
clock, tailored to the individual patient. However pain relief remains inadequate in cancer pain 
patients. 
 
• Non opioid analgesics 
• Opioid analgesics 
• Adjuvant drugs 
• WHO three step analgesic ladder 
• Advanced pharmacological strategies 
• Interventional strategies 
• Psychological therapies 
• Supportive therapies 
• Physical therapies 
• Anticancer therapies 
Acetaminophen (paracetamol) or nonsteroidal anti-inflammatory drugs (NSAIDs) are 
effective analgesics for patients with mild cancer pain and can be combined with opioids in 
patients with moderate to severe pain. Experience with the use of WHO ladder has shown that 
the simple principle of escalating from non-opioid to strong opioid analgesics is safe and 
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effective. Nonopioid analgesics prevent formation of prostaglandins produced in response to 
noxious stimuli, thereby decreasing the number of pain impulses received by the CNS. 
 OPIOIDS are very effective for the relief of moderate to severe pain. Many patients with cancer 
pain, however, become tolerant to opioids during long-term therapy. Therefore, increasing doses 
may be needed to continue to relieve pain. A patient's tolerance of an opioid or physical 
dependence on it is not the same as addiction (psychological dependence). Mistaken concerns 
about addiction can result in under treating pain. 
TYPES OF OPIOIDS : 
There are several types of opioids. Morphine is the most commonly used opioid in cancer pain 
management. Other commonly used opioids include hydromorphone, oxycodone, oxymorphone, 
methadone, fentanyl, meperidine (Demerol), tapentadol, and tramadol. 
 
 In most patients, side effects associated with the use of opioids can be easily managed with a 
combination of patient education and reassurance about the transient nature of sedation and 
emesis, careful selection of dose and route of opioid, and the use of additional drugs such as 
antiemetics and laxatives. 
 SIDE EFFECTS OF OPIOIDS: 
Nausea,constipation,vomitting 
 ADJUVANT DRUGS are used for difficult pain syndromes including neuropathic and bone 
pain. Among the agents frequently used for the management of neuropathic pain, tricyclic 
antidepressants, systemic local anesthetics, and baclofen have been traditionally used for 
dysesthetic pain, whereas anticonvulsants such as gabapentin, carbamazepine, and phenytoin 
have been more frequently used for the management of lancinating pain28. 
 
Incidental pain, defined as pain that is sudden and severely aggravated as a result of movement, 
swallowing, defecation, or urination, is usually controlled if the patient remains immobile or 
refrains from performing the painful maneuver. Other techniques to increase local control of 
incidental pain episodes include radiation therapy, orthopedic procedures, or neurological 
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procedures such as percutaneous cordotomy. Bisphosphonates are useful in relieving both the 
continuous and the incidental pain components in patients with bone cancer pain29. 
 
Pain can also be relieved by modification of the disease process when appropriate with surgery, 
chemotherapy, and radiotherapy. Other methods include psychological interventions, physical 
therapy, and complementary medicine. 
 
About 10% of patients may require interventional techniques (peripheral nerve blocks, 
autonomic nervous system blocks,radiofrequency lesions, and neurosurgical procedures) for 
some pain problems as part of a multimodal, multidisciplinary approach to pain control. 
 
For pain not controlled with oral medications, low doses of an opioid plus a local anesthetic can 
be delivered by the spinalor epidural routes to provide relief with relatively few side effects. 
Systems used for chronic intraspinal opioidadministration include percutaneous tunneled 
epidural or spinal catheters, tunneled catheters connected to subcutaneously implanted injection 
ports, and implanted infusion pump systems 30. 
 
3.12 INSULIN: 
Insulin is a two chain polypeptide hormone having 51 amino acids and MW about 6000.It is 
synthesized  by beta cells in the islets of Langerhans . It is made up of two chains, an A chain 
containing 21 amino acids and a B chain containing 30 amino acids, linked by two cysteine 
disulphide bridges. The gene for insulin is on the short arm of human chromosome 1131,32. 
3.13 FUNCTIONS OF INSULIN: 
Insulin is a hormone that is central to regulating carbohydrate and fat metabolism in the body. 
Insulin causes cells in the liver, muscle, and fat tissue to take up glucose from the blood, storing 
it as glycogen in the liver and muscles. Insulin is synthesized in significant quantities only in 
beta cells in the pancreas. When the beta cell is appropriately stimulated, insulin is secreted from 
the cell by exocytosis and diffuse into islet capillary blood. Insulin is secreted in primarily in 
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response to elevated blood concentrations of glucose. Some neural stimuli and increased blood 
concentrations of other fuel molecules, including amino acids and fatty acids also promote 
insulin secretion33. 
IMPORTANT FUNCTION OF INSULIN: 
Elevated concentrations of glucose in blood stimulate release of insulin, and insulin acts on cells 
throughout the body to stimulate uptake, utilization and storage of glucose. The effects of insulin 
on glucose metabolism vary depending on the target tissue. Two important effects are: 
• Insulin facilitates entry of glucose into muscle, adipose and several other tissues. 
• Insulin stimulates the liver to store glucose in the form of glycogen. 
In addition to its role of regulating glucose metabolism, insulin also 
• Stimulates lipogenesis  
• Diminishes lipolysis  
• Increases amino acid transport into cells  
• Modulates transcription  
• Altering the cell content of numerous mRNAs  
• Stimulates growth  
• DNA synthesis  
• Cell replication 35           
      3.14  FATE OF INSULIN: 
Insulin is distributed only extracellularly.It is a peptide gets degraded if given orally. The 
average daily secretion is about 2 mg (50 units).The half life of insulin is about 4 minutes. It 
is metabolized chiefly (about 80%) in liver and to a smaller extent in kidneys. About half is 
inactivated during first pass in the liver by insulin glutathione transhydrogenase which 
cleaves the molecule into A and B chains. The rest are inactivated in the kidney and other 
tissues by insulinases.31,32 
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         Insulin is metabolized in the liver, kidney, and muscle. Glucose stimulates insulin      
secretion through a series of regulatory steps that begin with its transport into the beta cells by 
the GLUT 2 transporter. Further metabolism of glucose via glucose- 6- phosphate and pyruvate 
generates ATP which inhibits the activity of ATP sensitive potassium channels. The inhibition of 
this potassium channel induces opening of voltage-dependent calcium channels and stimulation 
of insulin secretion36. 
Insulin promotes glucose entry across cell membrane into the cells of heart, muscle, adipose 
tissue and all other tissues except brain, liver, renal tubules, intestinal mucosa, islet cells and 
RBCs. Insulin Increases peripheral utilization of glucose, increases glycogenesis, decreases 
gluconeogenesis and favours conversion of glucose to fat. Insulin promotes protein anabolism 
and inhibits protein catabolism in liver, muscle and other cells. It also has a protein sparing 
action. Insulin promotes lipogenesis, inhibits lipolysis. Insulin promotes potassium and 
phosphate entry into cell. Insulin reduces sodium uptake 32. 
3.15 INSULIN RECEPTORS: 
   Insulin receptors are present in all cell membranes but their density depend on the cell type, for 
example liver and fat cells are very rich.  Insulin receptors are heterotetrameric glycoprotein’s 
consisting of  two extracellular alpha  and two transmembrane beta sub units linked together by 
disulfide bonds. It is oriented across the cell membrane as a heterodimer.The alpha subunits  
carry insulin binding sites while the beta  subunits have tyrosine protein kinase activity. Insulin 
acts on specific receptors located on the cell membrane of a cell. Excess insulin decreases and 
low insulin increases the number of insulin receptors.31,32. 
It has been postulated in many studies over the years that insulin is involved in the modulation of 
pain. However clinical studies regarding this is very scarce. 
 
 
3.16 CLINICAL STUDY ON PAIN: 
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A clinical study reported on the influence of morphine and ibuprofen on endogenous insulin and 
various biochemical parameters in patients with cancer pain. The results of the study showed 
serum insulin values in cancer patients showed significant increase although no significant 
differences in blood glucose, HDL, albumin and total protein level17 . 
In a study it was reported high insulin level in patients with pain in the neck, shoulder and back. 
The study revealed physiological and  psychological have been proposed to link stress and 
musculoskeletal pain. The study showed changes in P-endothelium , S-insulin, P-fibrinogen, S-
testosterone, S-albumin, and S-growth hormone37. 
Another clinical study in prader will syndrome patients (PWS) revealed, thermal and pain 
thresholds were significantly higher than in healthy and obese people. Most of the sensory 
thresholds were altered in PWS people. Serum insulin levels were significantly increased and 
QUICKI (quantitative insulin sensitivity check index) decreased38. 
A study was done to show a possible relationship between pain and insulin level in various 
painful conditions like trauma, arthritis, toothache, cancer pain. The magnitude of this 
relationship was observed more in cancer pain (unpublished data.) 
A study reports in humans, Insulin stimulates synthesis of the vasoconstrictor peptide endothelin-
1 (ET-1) by cultured vascular endothelial cells39.  
A study revealed acute severe pain decreases insulin sensitivity, primarily by affecting 
nonoxidative glucose metabolism in humans. Ten healthy male volunteers underwent two 
randomly sequenced hyperinsulinemic-euglycemic clamp studies 4 weeks apart. Self-controlled 
painful electrical stimulation was applied to the abdominal skin for 30 min, , to a pain intensity 
of 8 on a visual analog scale of 0-10, just before the clamp procedure. The study reported a 
twofold to threefold increase in concentrations of epinephrine, cortisol, growth hormone, 
glucagon and free fatty acids during pain40.  
In a study it was reported that in In vitro, insulin-like growth factor-I (IGF-I) has been shown to 
prevent neuronal apoptosis, to increase axonal growth, and to support myelination. But by using 
a double-blind, placebo-controlled design, 40 patients were randomized to treatment with 
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recombinant human IGF-I or placebo for 6 months. There were no significant adverse events and 
minor adverse events occurred equally in both groups. IGF-I was safe, but did not improve 
symptoms in this 6-month trial41. 
Another study analyzed blood plasma biochemical parameters in patients with pain of vascular 
origin. The biochemical parameters such a s C reactive protein, total protein, albumin, total 
cholesterol, HDL and LDL cholesterol, glucose, triglycerides, reduced glutathione, 
malondialdehyde (MDA), and total antioxidative capacity changed in relation to pain intensity. 
This study also stated that at different time intervals, pain intensity was related to different 
biochemical markers. This study finally concluded blood plasma changes might play an 
important role in pain assessment and pain management42. 
Another study was done to investigate biochemical parameters in the blood serum can establish 
and discriminate pain intensity of different etiology.  The patients with acute pancreatitis, 
patients with bone fractures and patients without pain were included in this study. Whole serum 
proteins, albumin, C-reactive protein, glucose, total cholesterol, LDL-cholesterol, HDL-
cholesterol, triacylglyceroles (triglycerides), apolipoprotein-B and electrophoretic levels of 
alpha-lipoprotein, beta-lipoprotein and pre-beta-lipoprotein were analyzed.  The results of this 
study revealed in both diagnoses during persisting pain, the products of lipid metabolism such as 
triacylglyceroles and HDL-cholesterol were enhanced together with glucose levels. 
Electrophoretic measurements, revealed higher levels of beta-lipoproteins in fractures, and 
increased values of pre-beta-lipoproteins and alpha-lipoproteins in both groups of patients 
suffering from pain. This study also stated acute stress generally influences glucose levels so that 
their increase cannot be considered as a specific marker of pain intensity43.  
 
 
 
3.17 PRECLINICAL STUDY ON PAIN: 
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The present study investigates the possible mechanisms of insulin antinociception in mice using 
the tail flick test. Mice were treated with insulin and the antinociceptive effect of modulators of 
5-HT, NMDA, dopamine, opioids, potassium and calcium channels was tested, followed by 
blood sugar estimation. All drugs were given 30 min prior to insulin administration. Pretreatment 
with morphine (opioid agonist), 5-Hydroxytryptophan (5-HTP; 5-HT precursor), nicorandil 
(K(+) channel opener) and nimodipine (Ca(+) channel antagonist) significantly (p < 0.001) 
potentiated insulin antinociception, whereas naloxone (opioid antagonist), ketanserin (5-HT(2) 
receptor antagonist), pCPA (5-HT depleter), ondansetron (5-HT(3) receptor antagonist), L-dopa 
(dopamine precursor), reserpine (dopamine depleter), ketamine (NMDA receptor antagonist) and 
glibenclamide (K(+) channel blocker) significantly antagonized insulin antinociception (p < 
0.001). Results suggest that 5-HT, dopamine, NMDA, opioidergic receptors and potassium and 
calcium channels play a significant role in insulin analgesia18. 
A study reported both glucose and insulin pretreatment in rats in certain doses were found to 
potentiate and prolong significantly the analgesic action of morphine22. 
The analgesic effect of sodium salicylate was doubled by the administration of insulin. The 
analgesic action of sodium salicylate was estimated by its prolongation of reaction time to a 
thermal stimulus and its level in tissue was determined chemically. Animals receiving insulin 
were given sufficient glucose to prevent hypoglycemia. Insulin injection doubled the analgesic 
effect of sodium salicylate and doubled its concentration in brain, heart and skeletal muscle. In 
alloxan-diabetic mice, both the action of S and its level in these tissues were decreased and were 
corrected by the administration of insulin. These results show that the transport of S across 
certain cell membranes is insulin-dependent20. 
Insulin attenuates chronic rather than acute pains through a mechanism mediated by dopamine, 
5-hydroxytryptamine and opioids without any hypoglycemic action. This study reveals that 
insulin induced antinociception may be due to some central mechanism. Intracerebroventricular 
doses of insulin dose-dependently reduced formalin-induced nociceptive responses19.  
Endogenous insulin level was significantly increased when antinociception was potentiated in 
mice. Flavanoid group of substances has been shown to elicit opioid mediators’ antinociceptive 
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response in experimental tools.44-46.This study reveals statistically insignificant glucose level 
changes. The hypo- and hyperglycemic conditions were induced physiologically through swim 
stress and external dextrose administration respectively in mice. The anti-nociception was 
assessed by acetic acid assay, blood glucose measured using glucometer and serum insulin by 
radioimmunoassay. A reduction in blood glucose level and elevation in serum insulin level when 
compared with flavones treatment was observed21. 
Insulin receptors are widely but unevenly distributed in the brain. Insulin has been reported to be 
involved in the regulation of neurotransmitters release. The results of this study showed that 
insulin has no analgesic activity; however, it caused significant central inhibitory effects by 
decreasing both locomotor activity and also decreased the exploratory behavior. The study 
concluded insulin has several neuropharmacological effects47. 
A study aimed to find out the antinociceptive effect of insulin and its combinations with 
resveratrol and curcumin in attenuating diabetic neuropathic pain. The study also examined the 
effect of these combinations on tumor necrosis factor-alpha (TNF-alpha) and nitric oxide (NO) 
levels in streptozotocin (STZ) induced diabetic mice. Four weeks after a single intraperitoneal 
injection of streptozotocin , mice were tested in the tail immersion and hot-plate assays. Diabetic 
mice exhibited significant hyperalgesia along with increased plasma glucose and decreased body 
weights compared with control mice. Chronic treatment with insulin and its combinations with 
antioxidants significantly attenuated thermal hyperalgesia and the hot-plate latencies. There was 
a significant inhibition of TNF-alpha and NO levels . These results indicate an antinociceptive 
activity of resveratrol and curcumin and point towards the beneficial effect of these combinations 
with insulin in attenuating diabetic neuropathic pain, possibly through the participation of NO 
and TNF-alpha48.  
A study reported systemic administration of clonidine and yohimbine respectively produced 
dose-dependent analgesic and hyperalgesic effects in control animals. Both of these phenomena 
were impaired in chronically diabetic animals. But insulin-treated diabetics displayed 
supersensitivity to clonidine's antinociceptive effect, especially at low doses49. 
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Diclofenac, dipyrone, ketorolac, lysine acetyl salicylate, and sodium salicylate were injected 
intradermally into mice tails and evaluated the tail-flick response to radiant heat. These results 
were compared with intraperitoneally injected controls. This study also evaluated the ability of 
naloxone to reverse the observed effects. The results of the study suggested local, but not 
systemic, administration of NSAIDs produced antinociception in the tail-flick thermal assay. The 
endogenous opioid system contributes to the peripheral anti-nociceptive effects of dipyrone, but 
not to that of diclofenac, ketorolac, lysine acetyl salicylate, or sodium salicylate, suggesting 
differences in the mechanisms of action among the NSAIDs50. 
A preclinical study stated one of early signs of diabetic neuropathy in STZ-treated rats, 
mechanical hyperalgesia, can be triggered by moderate insulinopenia, irrespective of glycemic 
status of the animals. This study evaluated the role of insulinopenia in nociceptive abnormalities 
in the streptozotocin (STZ) rat model of diabetes to test the hypothesis that, in addition to 
hyperglycemia, impairment of insulin signaling may be involved in progression of neuropathy.. 
The pain thresholds observed did not correlate with blood or nerve glucose or sorbitol levels, but 
both correlated with plasma insulin level in STZ-normoglycemic rats, and low-dose insulin 
replacement normalized the pressure threshold without affecting blood glucose level51.  
Enkephalins may have a neurotransmitter role in both brain and peripheral tissues and that 
methionine- and leucine-enkephalin haves eparate neuronal functions. The highest proportions of 
leucine-enkephalin were found in the cerebral cortex and hippocampus.In painful condition 
endogenous,opioid peptides play an important role in pain perception52. 
A study reported that some factor(s) derived from spleen mononuclear cells is the prime factor 
involving the insulin-insensitive mechanisms for the reduction of mu-opioid agonist-induced 
antinociception during the severe stages of diabetes53. 
 Clonidine induced antinociception is independent of its hyperglycemic action. In contrast to 
morphine, clonidine induced antinociception seems not to involve ATP sensitive potassium 
channels; rather its antinociception is enhanced by the blockade of these channels. This 
enhancement is attributed partially to an adrenergic mechanism excluding the opioid pathways. 
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The results favour the contention that the mechanisms K involved in the antinociception induced 
by clonidine and morphine are different54 . 
 Another study reports that 7-hydroxy flavone induces antinociception like morphine, utilize 
ATP sensitive potassium channel at the cellular level .The results of this study reveals no cause-
effect relationship between the changes in the glycaemic and algesic state. But insulin which is 
controlled by ATP sensitive potassium channel at the cellular level modulates antinociception 
exhibiting a cause-effect relationship between them55. 
The effects of pretreatment with protein kinase C and protein kinase A inhibitors on the 
intraventricular insulin-induced attenuation of the antinociceptive effect of [D-Ala2, N-MePhe4, 
Gly-ol5]enkephalin (DAMGO) were studied in mice. Intracerebroventricular (i.c.v.) pretreatment 
with insulin dose- and time-dependently attenuated the antinociceptive effect of i.c.v. DAMGO 
in mice. These results suggest that the reduction of DAMGO-induced antinociception by insulin 
in mice may be, in part, due to the activation of protein kinase C followed by the activation of 
tyrosine kinase56.  
 Another study reported effects of intravenous sodium salicylate administration on plasma 
concentrations of insulin, free fatty acids (FFA) and glucose  in intact, anaesthetized dogs both 
during basal and isoprenaline stimulated lipolysis. In both situations sodium salicylate reduced 
the plasma concentrations of insulin. The reduction was associated with decreased plasma FFA 
concentrations and FFA turnover rate, while plasma glucose concentrations remained unaltered. 
The reduced plasma insulin concentrations effected by sodium salicylate is most likely secondary 
to the concomitant fall in plasma FFA concentrations due to inhibition of FFA mobilization from 
adipose tissue57. 
 
3.18 CIRCADIAN RHYTHM: 
Cells are the fundamentals of life. All life’s processes happen in and by cells. One of the most 
amazing characteristics of cells is the fact that they sense what time it is. We humans possess a 
‘biological clock’ . During the night our body works differently from the daytime. We have a lot 
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of different clocks in our body, possibly even one in every cell. Homeostasis is a system that 
makes the organism - up to a certain level - independent of its environment. Homeostasis is the 
possibility every living system has to keep its inner system balanced, like our body keeps its 
temperature constant, independently of the outside temperature. Many processes happen adapted 
to day or night, or to the seasons. Often organisms are so adapted to day and night that they have 
a system that causes the adaptation already before night falls or morning begins. Biological 
clocks take care that things happen at the right time. Homeostasis is nowadays seen as one of the 
fundamental aspects of life, having a biological clock may be as fundamental. The best way for 
an organism to keep its homeostasis is to prepare itself in time before a change occurs. 
DEFINITIONS: 
CHRONOBIOLOGY: Derived from chronos (time), bios (life), and logos (study of) is the 
objective description of biological time structures and plays an important role in medicine. 
CHRONOPHARMACOLOGY: is the science concerned with the variations in the 
pharmacological actions of various drugs over a biological timings and endogenous periodicities.  
Chronobiology, studies the biological rhythms: 
CIRCADIAN RHYTHM: is defined as oscillations in the biological, physiological and 
behavioral function of an organism with a periodicity of 24 hrs. lasts about one day, like the 
sleep-waking rhythm, the body temperature, but also our sensitivity to pain or alcohol, reaction 
time, levels of hormones in the blood etc. Many patterns of change in plants and animals happen 
every day, always after about 24 hours. This circadian rhythm is the best known and probably 
most general rhythm in living creatures.  
 Biological clock  is a miniscule piece of the brain (20 000 cells in all) just above the chiasma 
opticum (the place where the optic nerves are crossing). The suprachiasmatic nucleus (SCN) is 
no bigger than a quarter of a cubic millimetre. Because it is so close to the optic nerve it can get 
information directly from the eyes. The SCN is the site of the central pacemaker capable of 
synchronizing the cellular rhythms to produce observable circadian rhythms in different 
physiologic measures58,59.  
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 Pain due to several pathological conditions exhibits temporal variations in intensity throughout 
the circadian cycle61.  
Circadian patterns of pain experience have been studied in various clinical disease states. For 
example, pain in rheumatoid arthritis occurs mostly at the beginning of the day62 whereas pain 
due to osteoarthritis occurs mostly at the end of the day63.The  migraine headaches showed a 
circadian pattern with more attacks occurring in the morning hours (08:00–12:00) compared to 
midnight.64 Also, the circadian pattern of dental pain were maximal in the early afternoon and 
minimal in the early morning.65.This clearly indicates that circadian rhythm influence pattern of 
pain in various diseases. 
3.19 CIRCADIAN  RHYTHM OF PAIN: 
The circadian (24-h) time structure showed great importance to the practice of medicine and 
pharmacotherapy of patients. . Rhythmicity in the pathophysiology of disease is one basis for 
chronotherapeutics. For effective treatment, purposeful variation in time of the concentration of 
medicines in synchrony with biological rhythm determinants of disease activity. Also a second 
basis to control the undesired effects of medications, especially when the therapeutic range is 
narrow and the potential for adverse effects high, which is the case for cancer drugs. A third 
basis is to meet the biological requirements for frequency-modulated drug delivery, which is the 
case for certain neuroendocrine peptide analogues66. 
Pain varies tremendously from patient to patient. Intensity of pain varies according to time of 
day. A circadian pattern of pain was found in patients suffering from pain produced by different 
diseases. For instance, highest toothache intensity occurred in the morning, while biliary colic, 
migraine, and intractable pain were highest at night. Patients with rheumatoid arthritis reported 
peak pain early in the morning, while those with osteoarthritis of the knee indicated that the 
maximal pain occurred at the end of the day. The effectiveness of opioids appears also to vary 
according to time of day, but large differences in the time of peak and low effects were found. . 
Investigators found that peak pain intensity and narcotic demands occurred early in the morning, 
while others found maximal pain at the end of theday2. 
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 The modulatory effects of sleep and circadian rhythmicity on glucose regulation appear to have 
important clinical implications for the diagnosis and treatment of abnormalities in carbohydrate 
metabolism67. 
A study reported dosing-time-dependent changes in the effect and toxicity of morphine were 
seen in mice keptunder 12h light and dark cycles. The magnitude of the analgesic effect of 
morphine depended on dosing time, with minimum effect at 02:00 h and maximum effect at 
14:00 h. The serum hepatic enzyme levels of AST and ALT increased after dosing morphine at 
02:00 and 14:00 h. However, hepatic glutathione, which is involved in the detoxification of 
chemical compounds, significantly decreased after i.p. morphine injection at 02:00 but not at 
14:00 h. The results suggest that the analgesic effect of morphine is greater after dosing during 
the resting than during the activity phase of mice that have been induced with bradykinin-
mediated pain. Drug-induced hepatic damage as inferred by GSH alteration, however, may be 
greater after dosing during the active phase68. 
The pharmacological effects and toxicity of KE-SI-TO (KST), analgesic and antipyretic drug, 
was investigated depending on the dosing time in mice. Circadian rhythms were demonstrated 
for analgesic and hypothermal effects of KST with higher values in the dark and lower ones in 
the light. Injection of KST resulted in a parallel increasing in latency to hot plate and a parallel 
decreasing in rectal temperature. KST induced toxicity was also observed depending on the 
dosing  time69. 
The fish under dimecron (an organophosphate pesticide) toxicity was investigated by estimating 
the serum levels of T3 (triiodothyronine), T4 (thyroxine), cortisol, prolactin and insulin in 
control and sub-lethal  dimecron-exposed fish for 1, 6, 12, 24h and 5 days. The fish exposed  to 
sub-lethal concentration of dimecron showed varying changes in the levels of these serum 
hormones.The study showed  reduced levels of thyroid hormone (T3) as well as the 
glucocorticoid hormone (cortisol) in the the fish which indicated they maintained a  low 
metabolic rate, which is advantageous for the fish to indirectly reduce the toxic impact of the 
pesticide.Also elevated levels of prolactin were observed which indicated hydromineral 
regulatory effect of the hormone , and increased insulin level in the fish under pesticide stress is 
indicated  its role in favoring an adaptive tissue glycogenesis besides a possible increased 
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lipogenesis to sequester the pesticide residue thereby reducing the toxic effect of the pesticide. 
The prolonged exposure of the fish (for 5 days) to sub-lethal dimecron appeared to exhibit a 
uniform recovery response in the different hormonal levels of the fish70. 
A study reported the time at which acetylsalicylic acid is administered is  important in the actions 
of acetylsalicylic acid. The rhythmic patterns of acetylsalicylic acid induced analgesia and 
hypothermia resembled overall the rhythms occurring in the non-drugged state. Injection of 
acetylsalicylic acid resulted in a parallel increase in latency to hot plate and a parallel decrease in 
rectal temperature.  Also a significant circadian rhythm in acetylsalicylic acid induced toxicity 
with the highest mortality at 17:00 and the lowest one at 05:00 . Dosing time dependent kinetics 
of salicylate seems to be related to the rhythm of toxicity of the drug71 . 
A study reported the hypothalamic–pituitary–adrenal axis (cortisol) and of the pineal gland 
(melatonin) altered functioning is responsible for the clinical circadian symptoms of RA.Human 
proinflammatory cytokine production exhibits a diurnal rhythmicity with peak levels during the 
night and early morning, at a time when plasma cortisol (anti-inflammatory) is lowest and 
melatonin (proinflammatory) is highest. Sex hormones also seem to be involved in circadian 
rhythms of RA symptoms. Increased pain intensity and sleep disturbances are observed during 
the luteal phase in patients who have RA, when estrogen (and progesterone) levels would be 
higher than in the follicular phase72. 
Another study revealed pain and pain intensity is circadian time dependent. Adequate pain relief 
is possible by taking this into account and thus developing new chronotherapeutic strategies and 
drug delivery systems. 
The study  confirmed circadian, circaseptan or circannual variations were seen in experimental 
inflammation and in patients with arthritis diseases. Morning stiffness observed in RA patients 
has become one of the diagnostic criteria of the disease. The  data showed  that signs and 
symptoms of rheumatoid arthritis (RA) vary between individuals, within a day and between 
days. The results of the study revealed circadian and circannual variations in the effectiveness, 
toxicity and pharmacokinetics of NSAID (non-steroidal anti-inflammatory drugs). A review of 
the available data suggests that peak and trough values found in different arthritic diseases do not 
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occur at the same hour of the day and that the side effects produced by NSAID are more 
important after the morning than the evening administration73. 
The day/night pattern in leptin is  caused by the combined effects of  endogenous circadian 
pacemaker and day/night patterns in behaviors. The data imply that alterations in the sleep/wake 
schedule would lead to an increased daily range in circulating leptin, with lowest leptin upon 
awakening, which, by influencing food intake and energy balance, could be implicated in the 
increased prevalence of obesity in the shift work population74.
  
 
 
AIM AND OBJECTIVE 
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4. AIM & OBJECTIVE 
• To estimate  the amount of endogeneous insulin level and glucose level in cancer 
pain patients during day and night cycle 
 
                     
 OBJECTIVE 
• To determine the serum insulin level and glucose level in cancer pain patients taking 
opioid and Nonopioid analgesics and in cancer patients without pain during day and 
night cycle. 
• To evaluate the role of endogenous insulin in pain threshold and to assess insulin’s     
antinociceptive activity. 
• To evaluate the role of circadian rhythm on endogenous insulin level during day and 
night cycle. 
• To evaluate the role of circadian rhythm on glycemic level during day and night 
cycle.
  
PLAN OF WORK 
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5.   PLAN OF WORK 
• Identification of scope of work 
• Literature survey 
• Preparation of protocol for study 
• Designing the Performa 
• Obtaining approval from the ethical committee 
• Obtaining consent from the hospital 
• Data collection 
• Analysis of the data 
• Blood sample collection 
• Insulin ELISA KIT and its proper storage 
• Estimation of serum insulin level using DRG insulin kit and glucose level using 
glucometer 
• To evaluate the role of circadian rhythm on endogenous insulin and glycemic level 
during day and night cycle 
• To assess the relation between serum insulin level and pain in patients with cancer pain 
patients.
  
METHODOLGY 
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6. METHODOLOGY 
      6.1 Study type:        
A Prospective study 
6.2 Study site:      
Erode cancer centre, Erode 
6.3 Sample size:     
22 patients 
Control group     :  6 cancer patients without pain 
Group A              :  8 cancer patients undergoing opioid treatment 
Group B             :   8 cancer patients undergoing   Nonopioid treatment  
6.4 Study Duration:      
  8 months  
6.5 Ethical clearance: 
 Ethical committee clearance approval were granted for this study by the institutional ethical 
committee (IEC),Swami Vivekananda college of pharmacy to carry out this work.  
    6.6  Patient selection: 
Inclusion criteria:  
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z Study population includes cancer patients undergoing opioid and nonopioid treatment and 
cancer patients without pain(control group) 
z Age 30-70 years 
 
 
Exclusion criteria:  
z Patients were excluded, 
z If they are unable to comply with protocol requirements 
z Patient with diabetes,hyperlipidemia,cardiovascular complications, liver and  renal 
dysfunction 
z Patients taking corticosteroids. 
       6.7 Patient data entry form:  
Patient data entry form included patient details such as name, age, sex ,height, weight, 
bodymassindex, education, occupation, past medical history, past medication history, family 
history, social history, dietary habits, type of cancer, stage of cancer, site of pain, VAS score, 
treatment regimen for both cancer and pain 
   6.8 Blood sample collection: 
 5 ml of peripheral venous blood was collected by vein puncture using a dry disposable syringe 
z Approximately 5ml each 4 times a day 
z Morning      :6 am 
z Afternoon    :12 pm 
z Evening       :6 pm 
z Midnight      :12 am 
  6.9 Parameters to be investigated: 
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 All the cases, control, cancer patients with pain and cancer patients without pain will be 
considered for the investigation of insulin and glucose level. 
 
 
6.10 Estimation of glucose levels: 
 Glucose levels were estimated using glucometer (Accue Sure, Microgene Diagnostic 
systems Pvt. Ltd., New Delhi). A drop of  blood  was collected  and placed on glucometer strip. 
The values of glucose levels, as indicated in the display screen, were recorded. 
 6.11 Estimation of serum insulin:  
Serum insulin level was estimated by ELISA method by using DRG INSULIN KIT . 
Name and intended use: The DRG Insulin Enzyme Immunoassay Kit provides materials for 
the quantitative determination of insulin in serum and plasma. This assay is intended for in vitro 
diagnostic use only.  
Insulin is the principal hormone responsible for the control of glucose metabolism .it is 
synthesized in the β-cells of the islets of Langerhans as the precursor, proinsulin,which is 
processed to form c-peptide and insulin. both are secreted in equimolar amounts  into the portal 
circulation. the mature insulin molecule comprises 2 polypeptide chains, the A chain and B 
chain(21 and 30 amino acids respectively).the 2 chains are linked together by 2 inter-chain 
disulphide bridges. There is also an intra-chain disulphide bridge in the A chain. 
 Secretion of insulin is mainly controlled by plasma glucose concentration, and the hormone has 
a number of important metabolic actions. its principal function is to control the uptake and 
utilization of glucose in peripheral tissues via the glucose transporter. This and other 
hypoglycemic activities, such as the inhibition of hepatic gluconeogenesis and glycogenolysis 
are counteracted by the hyperglycemic hormones including glucagon, epinephrine (adrenaline), 
growth hormone and cortisol. 
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Insulin concentrations are severely reduced in insulin-dependent diabetes mellitus(IDDM) and 
some other conditions such as hypopituitarism.insulin levels are raised in non-insulin dependent 
diabetes mellitus(NIDDM),obesity, insulinoma, and some endocrine dysfunctions such as 
Cushing’s syndrome and acromegaly. 
 
PRINCIPLE OF THE TEST: 
The DRG insulin ELISA kit is a solid phase enzyme-linked immunosorbent assay (ELISA) 
based on the sandwich principle. The micro titer wells are coated with a monoclonal antibody 
directed towards a unique antigenic site on the insulin molecule. An aliquot of patient sample 
containing endogenous insulin is incubated in the coated well with enzyme conjugate, which is 
an anti-insulin antibody conjugated with Biotin. After incubation the unbound conjugate is 
washed off. During the second incubation step Streptavidin Peroxidase Enzyme Complex binds 
to the biotin- anti –insulin antibody. The amount of bound HRP complex is proportional to the 
concentration of insulin in the sample. Having added the substrate solution, the intensity of 
colour developed is proportional to the concentration of insulin in the patient sample. 
Kit components: 
Content of the kit: 
1. Micro titer wells,12×8 strips, 96 wells .Wells coated with anti insulin monoclonal 
antibody 
2. Zero standard, 1 vials, 3ml, ready to use 
3. Standard (standard1-5), 5 vials, 1ml, ready to use, 
Concentrations: 6.25-12.5-25-50and 100µLu/ml 
4. Enzyme Conjugate,1vial,5 ml, ready to use, mouse monoclonal anti insulin 
conjugated to biotin 
5. Enzyme Complex,1 vial,7 ml, ready to use, Streptavidin HRP complex 
6. Substrate solution ,1 vial,14 ml, ready to use,TMB 
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7. Stop Solution,1 vial,14 ml, ready to use, contains 0.5M H2SO4 
8. Wash Solution,1 vial,30 ml(40×concentrated) 
Equipment and material required but not provided 
¾ A micro titer plate calibrated reader(450±10nm) 
¾ Calibrated variable precision micropipettes 
¾ Absorbent paper 
¾ Aqua dest. 
Storage and stability of the kit: 
When stored at 2-8 c unopened reagents will retain reactivity until expiration date. All opened 
reagents and micro titer wells must be stored at 2-8^c.Once the foil bag has been opened ,care 
should be taken to close it tightly again. 
Preparation of reagents: 
Allow all reagents and required number of strips to reach room temperature prior to use. 
Wash solution: 
Dilute 30 ml of concentrated wash solution with 1170 ml deionized water to a final volume of 
1200 ml.The diluted wash solution is stable for 2 weeks at room temperature. 
Specimen collection: 
Serum or plasma can be used in this assay. Serum is used here 
SERUM: collect blood by venipuncture, allow to clot, and separate serum by centrifugation at 
room temperature. 
Assay procedure: 
• Secure the desired number  of micro titer wells in the holder 
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• Dispense 25µl of each standard,controls,and samples with new disposable tips into 
appropriate wells 
• Dispense 25µl enzyme conjugate into  each well 
• Thoroughly mix for 10 seconds. it is important to have a complete mixing in this step 
• Incubate for 30 minutes at room temperature without covering the plate 
• Briskly shake out the contents of the wells. rinse the wells 3 times with diluted wash 
solution. strike the wells sharply on adsorbent paper to remove residual droplets 
• Add 50µl of enzyme complex to each well 
• Incubate for 30 minutes at room temperature 
• Briskly shake out contents of the wells. Rinse the well 3 times with diluted wash solution. 
Strike the wells sharply on adsorbent paper to remove residual droplets 
• Add 50µl of substrate solution to each well 
• Incubate for 15 minutes at room temperature 
• Stop the enzymatic reaction by adding 50µl of stop solution to each well 
• Read the OD at 450±10 nm with a micro titer plate reader within 10 minutes after adding 
the stop solution. 
  
RESULTS 
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7. RESULTS 
 
Chronological influence on insulin level and glycemic status is a prospective case control study  
done  in Erode Cancer centre, Erode. This study was carried out for a period of 9 months. Out of 
50 patients screened we recruited 22 patients for this study whose age ranged from 30- 70 years. 
The study protocol was approved by the Institutional Research Ethical Committee of Swamy 
Vivekananda College of pharmacy and granted permission for the conduct of study. 
 
Patients were categorized as Group A, Group B, Group C for the study. Group A included 8 
patients taking opiod drugs, Group B included 8 patient taking nonopiod drugs and Group C 
included 6 control patients without pain. Patient with diabetes, hyperlipidemia, cardiovascular 
complications, liver and renal failure, Patients taking corticosteroids were excluded from the 
study. Patient data entry format was prepared to record patients’ demographic details, past 
medical and medication history, family history and pain score. Pain was assessed in patients 
using Visual Analogue Scale. Blood samples were collected from patients four times a 
day(12PM,6PM,12AM,6AM)with their consent. Biochemical parameters such as insulin and 
glucose levels were estimated. Serum Insulin level were determined by ELISA method using 
DRG INSULIN KIT. Glucose levels were estimated using glucometer. 
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7.1 DEMOGRAPHIC DETAILS: 
7.1.1. Gender distribution: 
All the patients included for the study were divided into opioid , nonopioid and control group. In 
control group,3 males and 3 females were present. Opioid group included 4 male patients and 4 
female patients. And in nonopioid group 4 males and 4 females were present. Amongst 22 
participants in the study (11) 50% were males and (11) 50% were females. 
 
Figure 1 .Gender distribution for different groups of study population 
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7.1.2.Age distribution: 
Age distribution showed that (12) 54.5%were in 30-55 age group, (10) 45.4% were in 56-70 age 
group .In opioid group 5 males(62%) and 3 females(37.5)were present. In nonopioid group 
4(50%) males and 4(50) females and in control group  3 males(50%) and 3 female(50%) patients 
present. 
 
Fig 2. Age distribution for different groups of study population 
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7.1.3.BMI profile: 
 Among 8 patients in opioid group, 5(62.5%)were normal weight, 37.5% were overweight. 
Among 8 patients in nonopioid group, 4(50%) were normal weight, 3(37.5%) were overweight 
and 1(12.5%) were obese. In control group 3(50%) were of normal weight 2(33.3%) were 
overweight and 1(16.65%0 were obese. Out of the total participants in the study 9(40.9%) were 
normal weight,11(50%) were overweight and 2(9.09%) obese. 
 
Fig 3. BMI distribution for different groups of study population 
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7.1.4. Education status:  
Out of the total 22 participants in the study group, analysis of their education level indicate that 
(9)40.9% individual completed SSLC,(10)45.4% had secondary school level education,(3) 
13.6%individual were graduates. 
 
 
Fig 4. Education level for different groups of  study population 
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7.1.5. Occupation profile of study population 
Amongst the 22 patients (8) 36.3% were coolie,(4) 18.8% were drivers,(10) 45.4% were house 
wife. 
 
 
Fig: 5. Occupation level for different groups of study population 
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7.1.6. Social history profile for different groups of study participants 
Among 22 patients in the study (8)31.8% were smokers,(14)63.6% were non-smokers,(8) 36.3% 
were alcoholics ,(14)63.6% were non alcoholics 
 
 
Fig: 6. Social history for different groups of study population 
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Table 1. Demographic details of study group 
 
Parameter Number of subject (%) 
Opioid 
(N=8) 
Non 
opioid 
(N=8) 
Controls 
(N=6) 
Total 
(N=22) 
Sex 
Men 4(50%) 4(50%) 3(50%) 11(50%) 
Women 4(50%) 4(50%) 3(50%) 11(50%) 
Age     
30-55 5(62%) 4(50%) 3(50%) 12(54.5%) 
56-70 3(37.5%) 4(50%) 3(50%) 10(45.4%) 
BMI 
25 5(62.5%) 4(50%) 3(50%) 9(40.9%) 
25-29.9 3(37.5%) 3(37.5%) 2(33.3%) 11(50%) 
30 0(0%) 1(12.5%) 1(16.65%) 2(9.09%) 
Education status 
Lliterature 
SSLC 4(50%) 3(37.5%) 2(33.3%) 9(40.9%) 
HSE 2(25%) 5(62%) 3(50%) 10(45.4%) 
UG 2(25%) - 1(16.6%) 3(13.6%) 
Occupation 
Coolie 3(37.5%) 2(25%) 3(50%) 8(36.3%) 
Driver 2(25%) 2(25%) - 4(18.8%) 
House wife 3(37.5%) 4(50%) 3(50%) 10(45.45%) 
Smoking History 
Smoker 3(37.5%) 2(25%) 3(50%) 8(36.3%) 
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Non-
smoker 
5(62.5%) 6(75%) 3(50%) 14(63.6%) 
Alcoholism 
Yes 3(37.5%) 2(25%) 3(50%) 8(36.3%) 
No 5(62.5%) 6(75%) 3(50%) 14(63.6%) 
 
 
7.2)Classification of study participants  based on type of cancer  
Out of 22cancer patients in the study, most of them  were suffering from cervical cancer 
(3)13.6%,breast cancer  ( 3)13.6% and cancer of oral( 4)18.8%.In this group of patients most of 
them  were prescribed with opioid drugs which indicated they suffered severe pain.(3) 
13.6%were suffering from cancer of stomach  and  oesophagus and neck cancer.1(4.05%) was 
suffering from cancer of ovary and uterus The remaining ( 2)9.09% patients were categorized as 
other type of cancer which included cancer of lungs and peripheral nerve sheeth tumor. 
             Table 2.Classification of Cancer 
 
SL 
NO 
TYPES OF CANCER No; in total groups in 
% 
1 Cancer of Cervix 3(13.6%) 
2 Cancer of Breast 3(13.6%) 
3 Oral Cancer 4(18.8%) 
4 Esophagus cancer 3(13.6%) 
5 Stomach cancer 3(13.6%) 
6 Neck cancer 3(13.6%) 
7 Other types of cancer 2(4.05%) 
 
 
Results were analyzed using computerized statistical package of Graph pad Instat software. The 
statistical significance was tested by the analysis of variance (ANOVA) and Tukey - Kramer 
Multiple Comparisons Test. All data are presented as mean ± SD(SEM) 
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7.3)   Effect of circadian rhythm on serum insulin level 
7.3.1)   Effect of circadian rhythm on serum insulin level in opioid,nonopiod and control 
group at 6AM: 
 The results of the effect of circadian rhythm on serum insulin level at 6AM were shown in Table 
3 and Figure 7 . The mean serum insulin level in the control group of patients at 6AM 
was8±2.315 which was changed in nonopioid group to17.5875±2.847 and 31.3125±7.358 in 
opioid group. However at 6AM p value was found statistically significant between the three 
groups. 
 
 
Table.3 Effect of circadian rhythm on serum insulin level in opioid,nonopioid and control 
group at 6AM 
PARAMETER  OPIOID 
(n=8) 
 
NONOPIOID 
(n=8) 
 
CONTROL 
(n=6) 
 
P VALUE 
Serum insulin 
level in µIU/ml 
Mean±SD(SEM) 
 
31.3125±20.812 
(7.358) 
 
17.5875±8.053 
(2.847) 
 
8±5.671 
(2.315) 
 
P=0.O176* 
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Figure.7 Effect of circadian rhythm on serum insulin level in opioid,nonopioid and control 
group at 6AM. n=22; the values are expressed as mean ±SD(SEM); (one way ANOVA followed 
by Tukey’s multiple comparison Test)  
Tukey-Kramer Multiple Comparisons Test 
   opioid vs nonopioid                                   ns P>0.05 
   opioid vs control                                       * P<0.05 
   nonopioid vs control                                 ns P>0.05 
 
Table 3. Shows the serum insulin level in the control, opioid, nonopioid taking groups. 
Extremely significant level of insulin level is seen in both opioid and non-opioid taking patient 
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group as compared to control group. Serum insulin level is found to be higher in opioid taking 
group when seen with nonopioid groups which may be due to high pain level in opioid taking 
patients. 
 
7.3.2)   Effect of circadian rhythm on serum insulin level in opioid,nonopioid and    control 
group at 12PM: 
 The results of the effect of circadian rhythm on serum insulin level at 12PM were shown in 
Table 4 and Figure 8.The mean serum insulin level in the control group of patients at 12noon 
was 7.4±2.584 which was changed in nonopioid group to 18.3625±3.087 and 33.05±4.510 in 
opioid group. However at 12PM p value was found statistically significant between the three 
groups. 
 
 
Table.4 Effect of circadian rhythm on serum insulin level in opioid,nonopioid and control 
group at 12PM 
 
PARAMETER 
 
OPIOID 
(n=8) 
 
NONOPIOID 
(n=8) 
 
CONTROL 
(n=6) 
 
P VALUE 
Serum insulin 
level in µIU/ml 
Mean±SD(SEM) 
 
33.05±12.757 
(4.510) 
 
18.3625±8.731 
(3.087) 
 
7.4±6.331 
(2.584) 
 
P=0.0005*** 
 
 
 
 
51 
 
 
 
 
 
 
SERUM INSULIN LEVEL AT 12PM
groups
se
ru
m
 in
su
lin
 le
ve
l
gr
ou
p A
gr
ou
p B
gr
ou
p C
0
10
20
30
40
 
Figure.8 Effect of circadian rhythm on serum insulin level in opioid,nonopioid and control 
group at 12PM. n=22; the values are expressed as mean ±SD(SEM); (one way ANOVA followed 
by Tukey’s multiple comparison Test)  
 
Tukey-Kramer Multiple Comparisons Test 
opioid vs non opioid                                                     *  P< 0.05 
opioid vs control                                                          *** P<0.001 
nonopioid vs control                                                   ns P>0.05 
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This shows that serum insulin level is found to be higher in opioid taking group when compared 
with Nonopioid group due to high pain level in this group.  
 
 
7.3.3)   Effect of circadian rhythm on serum insulin level in opioid,nonopiod and control 
group at 6PM: 
 The results of the effect of circadian rhythm on serum insulin level at 6PM were shown in Table 
5 and Figure 9. The mean serum insulin level in the control group of patients at 6PM was 
5.483±1.511 which was changed in nonopioid group to 69.1875±7.527 and13.7875±1.431 in 
opioid group. However at 6PM p value was found statistically significant between the three 
groups.  
 
 
 
Table.5 Effect of circadian rhythm on serum insulin level in opioid,nonopioid and control 
group at 6PM 
 
PARAMETER OPIOID 
(n=8) 
NONOPIOID 
(n=8) 
CONTROL 
(n=6) 
P VALUE 
Serum insulin 
level in µIU/ml 
Mean±SD(SEM) 
 
13.7875±4.047 
(1.431) 
 
69.1875±21.290 
(7.527) 
 
5.483±3.702 
(1.511) 
 
P=0.0001*** 
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Figure.9 Effect of circadian rhythm on serum insulin level in opioid,nonopioid and control 
group at 6PM. n=22; the values are expressed as mean ±SD(SEM); (one way ANOVA followed 
by Tukey’s multiple comparison Test) 
 
Tukey-Kramer Multiple Comparisons Test 
   opioid vs nonopioid                                                *** P<0.001 
   opioid vs control                                                      ns  P>0.05 
   nonopioid vs control                                               *** P<0.001 
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Table 5. shows the serum insulin level in the control, opioid,nonopioid taking groups. Extremely 
significant level of insulin level is seen in both opioid and non-opioid taking patient group as 
compared to control group. Serum insulin level is found to be higher in nonopioid taking group 
when seen with opioid groups. 
 
7.3.4)   Effect of circadian rhythm on serum insulin level in opioid,nonopiod and control 
group at 12AM: 
 The results of the effect of circadian rhythm on serum insulin level at 12AM were shown in 
Table 6 and Figure 10. The mean serum insulin level in the control group of patients at 12AM 
was 5.6333±1.568 which was changed in nonopioid group to 67.3375±10.864 and 10.325±1.761 
in opioid group. However at 12AM pvalue was found  statistically significant between the three 
groups. 
 
 
 
Table .6 Effect of circadian rhythm on serum insulin level in opioid,nonopioid and control group 
at 12AM 
 
PARAMETER OPIOID 
(n=8) 
NONOPIOID 
(n=8) 
CONTROL 
(n=6) 
P VALUE 
Serum insulin 
level in µIU/ml 
Mean±SD(SEM) 
 
10.325±4.980 
(1.761) 
 
67.3375±30.728 
(10.864) 
 
5.6333±3.842 
(1.568) 
 
P<0.0001*** 
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Figure.10 Effect of circadian rhythm on serum insulin level in opioid,nonopioid and control 
group at 12AM. n=22; the values are expressed as mean ±SD (SEM); (one way ANOVA 
followed by Tukey’s multiple comparison Test) 
 
Tukey-Kramer Multiple Comparisons Test 
   opioid vs nonopioid                                                    *** P<0.001 
   opioid vs control                                                        ns  P>0.05 
   nonopioid vs control                                                 *** P<0.001 
 
Table 6. shows the serum insulin level in the control, opioid,nonopioid taking groups. Extremely 
significant level of insulin level is seen in both opioid and non-opioid taking patient group as 
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compared to control group. Serum insulin level is found to be higher in nonopioid taking group 
when seen with opioid groups .This may be due to high pain level in nonopioid taking patients. 
This result shows that insulin level is increased at midnight in nonopioid taking patients From 
this understand that circadian rhythm influence on pain.  
 
The results of the above data is in concordance with the findings of  Nitya et al(2010),wherein 
reported relation between pain and insulin level is observed in  cancer pain patients whereas no 
change in the glucose levels. The results also coincides with the finding that insulin possess 
antinociceptive action and this antinociceptive effect could be due to hypoglycemia and release 
of endogenous opioid peptides ;Takeshita et al.Another  preclinical study reported  insulin is 
involved in the modulation of pain in animal. Serum insulin showed a significant rise whenever 
antinociceptive response was recorded irrespective of glycemic state;Rajendran et al(2001).The 
results of the study also coincides with the finding of Jacob et al;stated that acute severe pain 
decreases insulin sensitivity. So the mechanism of action may be due to the development of 
insulin resistance. These results thereby reveals that  in painful condition like cancer pain  
increased levels of insulin levels were observed when compared with control group. 
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 7.4)   Effect of circadian rhythm on blood glucose level: 
7.4.1)   Effect of circadian rhythm on blood glucose level in opioid,nonopioid and control 
group at 6AM: 
 The results of the effect of circadian rhythm on blood glucose level at 6AM were shown in 
Table 7 and Figure 11. The mean blood glucose level in the control group of patients at 6AM 
was 88.666±5.925  which was changed in nonopioid group to87.25±3.353  and 85.125±3.287  in 
opioid group However, these increase were statistically not significant (P>0.05). 
 
 
 
 
Table.7 Effect of circadian rhythm on blood glucose level in opioid,nonopioid and control 
group at 6AM. 
 
PARAMETER  OPIOID 
(n=8) 
NONOPIOID 
(n=8) 
CONTROL 
(n=6) 
P VALUE 
Blood glucose 
level in mg/dl 
Mean±SD(SEM) 
 
85.125±9.296 
(3.287) 
 
87.25±9.483 
(3.353) 
 
88.666±14.514 
(5.925) 
 
P=0.8315 
  NS 
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Figure.11 Effect of circadian rhythm on blood glucose  level in opioid,nonopioid and control 
group at 6AM. n=22; the values are expressed as mean ±SD(SEM); (one way ANOVA followed 
by Tukey’s multiple comparison Test)  
The above data reveals that, there was no statistical significant relationship between changes in 
blood glucose level (p>0.05) in control, opioid taking and nonopioid taking groups in cancer 
patients. 
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7.4.2)   Effect of circadian rhythm on blood glucose level in opioid,nonopiod and control 
group at 12PM: 
 The results of the effect of circadian rhythm on blood glucose level at 12PM were shown in 
Table 8 and Figure 12. The mean blood glucose level in the control group of patients at 12PM 
was 88.166±5.300 which was changed in nonopioid group to 86.5±2.471 and 84.625±3.545 in 
opioid group However, these increase were statistically not significant (P>0.05). 
Table.8 Effect of circadian rhythm on blood glucose level in opioid,nonopioid and control 
group at 12PM. 
PARAMETER  OPIOID 
(n=8) 
 
NONOPIOID 
(n=8) 
CONTROL 
(n=6) 
P VALUE 
Blood glucose 
level in mg/dl 
Mean±SD(SEM) 
 
84.625±10.028 
(3.545) 
 
86.5±6.990 
(2.471) 
 
88.166±12.983 
(5.300) 
 
P=0.8049 
    NS 
 
 
 
 
 
60 
 
BLOOD GLUCOSE LEVEL AT 12 PM
groups
bl
oo
d 
gl
uc
os
e 
le
ve
l
GR
OU
P A
GR
OU
P B
GR
OU
P C
0
20
40
60
80
100
 
 
Figure.12 Effect of circadian rhythm on blood glucose level in opioid,nonopioid and control 
group at 12PM. n=22; the values are expressed as mean ±SD(SEM); (one way ANOVA followed 
by Tukey’s multiple comparison Test) 
 
 
 
7.4.3)   Effect of circadian rhythm on blood glucose level in opioid,nonopiod and control 
group at 6PM: 
 The results of the effect of circadian rhythm on blood glucose level at 6PM were shown in table 
9 and figure 13. The mean blood glucose level in the control group of patients at 6PM was 
88±3.830 which was changed in nonopioid group to 86.625±2.521 and 87.25±3.427 in opioid 
group However, these increase were statistically not significant (P>0.05). 
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Table.9 Effect of circadian rhythm on blood glucose level in opioid,nonopioid and control 
group at 6PM. 
 
PARAMETER  OPIOID 
(n=8) 
NONOPIOID 
(n=8) 
CONTROL 
(n=6) 
P VALUE 
Blood glucose 
level in mg/dl 
Mean±SD(SEM) 
 
87.25±9.692 
(3.427) 
 
86.625±7.130 
(2.521) 
 
88±9.381 
(3.830) 
 
P=0.9586 
  NS 
                      
BLOOD GLUCOSE LEVEL AT 6 PM
groups
bl
oo
d 
gl
uc
os
e 
le
ve
l
GR
OU
P A
GR
OU
P B
GR
OU
P C
0
20
40
60
80
100
 
 
Figure.13 Effect of circadian rhythm on blood glucose level in opioid,nonopioid and control 
group at 6PM. n=22; the values are expressed as mean ±SD(SEM); (one way ANOVA followed 
by Tukey’s multiple comparison Test) 
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7.4.4)   Effect of circadian rhythm on blood glucose level in opioid,nonopiod and control 
group at 12AM: 
 The results of the effect of circadian rhythm on blood glucose level at 12AM were shown in 
Table 10 and Figure 14. The mean blood glucose level in the control group of patients at 12AM 
was 86.5±4.023  which was changed in nonopioid group to 85.25±2.610 and 83.625±3.262 in 
opioid group However, these increase were statistically not significant (P>0.05). 
 
Table.10 Effect of circadian rhythm on blood glucose level in opioid,nonopioid and control 
group at 12AM. 
 
PARAMETER  OPIOID 
(n=8) 
NONOPIOID 
(n=8) 
CONTROL 
(n=6) 
P VALUE 
Blood glucose 
level in mg/dl 
Mean±SD(SEM) 
 
83.625±9.226 
(3.262) 
 
85.25±7.382 
(2.610) 
 
86.5±9.854 
(4.023) 
 
P=0.8292 
   NS 
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Figure.14 Effect of circadian rhythm on blood glucose level in opioid,nonopioid and control 
group at 12AM. n=22; the values are expressed as mean ±SD(SEM); (one way ANOVA 
followed by Tukey’s multiple comparison Test) 
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The above data reveals that,there was no statistical significant  relationship between changes in 
blood glucose level(p>0.05) in control, opioid taking and nonopioid taking groups in cancer 
patients. 
The results of this study is in adherence with the findings of Nitya et al(2010),wherein reported 
relation between pain and insulin level in  cancer patients independent of the glucose levels. 
Another preclinical study reported that serum insulin showed a significant rise whenever 
antinociceptive response was recorded irrespective of glycemic state Rajendran et al(2001).The 
results also coincides with the finding that an i.c.v injection of insulin dose dependently 
attenuated the formalin induced antinociception, but it did not lower the blood glucose level even 
at the largest dose.T he results of this study coincides with these findings. 
 
 
  
 
Table 11.Influence of time on serum insulin level  in cancer  patients . 
        
PARAMETER 
             OPIOIDS          NONOPIOIDS 
 
 
 
Serum insulin 
level in µIU/ml 
Mean±SD(SEM) 
 
   12PM 6AM 6PM 12AM 
 
33.05±12.757 
(4.510)  
 
31.3125±20.812
(7.358) 
 
69.1875±21.290
(7.527)  
 
67.3375±30.728
(10.864)  
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In opioid taking group, serum insulin level showed an increase at 12pm and 6 am whereas in 
nonopioid taking group rise in insulin level was seen at 6pm and 12am.This clearly indicates that 
circadian rhythm shows a great influence in the insulin release 
 
Table 12. Influence of gender on insulin level in opioid taking cancer patients 
GENDER     6AM      12PM      6PM     12AM 
MALE      34.575       32.075      12.175      11.925 
FEMALE       30.05      34.025         15.4       8.75 
 
 
Table 13.Influence of gender on insulin level in nonopioid taking cancer patients 
GENDER 6AM 12PM 6PM 12AM 
MALE 20.725 20.975 76.5 73.457 
FEMALE 17.45 19.75 71.875 69.2 
There was no significant difference in insulin levels among both genders in opioid and nonopioid 
cancer patients.
  
 
DISCUSSION 
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8. DISCUSSION 
                The results of this study clearly demonstrates that endogenous insulin is involved  in 
the modulation of pain in different types of cancer and this is influenced by circadian rhythm.  
                A circadian rhythm is an endogenously driven roughly 24-hour cycle in biochemical, 
physiological, or behavioral processes. It is cell-autonomous. The information of the time of the 
day as relayed by the eyes travels to the clock in the brain, and, through that, clocks in the rest of 
the body may be synchronized. This is how the timing of, for example, sleep/wake, body 
temperature, and thirst, and appetite, periodic release of hormones are coordinately controlled by 
the biological clock. Circadian rhythm is linked to the light–dark cycle. Animals, including 
humans, kept in total darkness for extended periods eventually function with a free running 
rhythm. Each "day", their sleep cycle is pushed back or forward, depending on whether their 
endogenous period is shorter or longer than 24 hours. The environmental cues that reset the 
rhythms each day are called zeitgebers .The SCN (Suprachiasmatic Nucleus) is the central 
pacemaker capable of synchronizing the cellular rhythms to produce observable circadian 
rhythms58,59 . 
                    Most people experience pain in one way or other and take analgesics or pain killers 
to alleviate the pain. However the intensity of pain varies with times and this has been observed 
in much clinical painful condition. For example, pain in rheumatoid arthritis occurs mostly at the 
beginning of the day. The reason for high pain intensity is due to high production of cytokines 
during early morning and also plasma cortisol (anti-inflammatory) is lowest and melatonin 
(proinflammatory) is highest during this timings (Cutolo M et al)72   and thus clearly signals the 
influence of circadian rhythm on the modulation of pain over time. 
                         The involvement of endogenous insulin in the modulation of pain both in animals 
(Rajendran et al)21 and humans(Nitya et al)17 has been well documented. Circadian rhythm 
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variations show changes in insulin level, as evidenced in animals or humans. As endogenous 
insulin has been implicated in the modulation of pain and also stated that it is influenced by 
circadian rhythm, the pain perception at different time is obvious. 
                        Of the several painful clinical condition, cancer pain management remains a 
challenge and the mechanism underlying this is not clearly established. Previously it has been 
reported that there exists a relation between cancer pain and endogenous insulin (Nitya et 
al)17.However whether circadian rhythm influences such a relationship is not established and 
therefore the present study aimed to investigate the relation between endogenous insulin and pain 
in different cancers and also the influence of circadian rhythm on the relation between 
endogenous insulin and cancer pain. 
                        Earlier studies revealed that insulin produces analgesic response independent of 
the glycemic status(Takeshita et al)19 and the analgesic response was mediated through 5-
HT,dopamine,NMDA and opioid peptides and also potassium and calcium channels(Anuradha et 
al)18.Thus studies so far conducted established the relationship between endogenous insulin level 
and pain threshold independent of glycemic status. 
                        In this study it was observed, significant increase in endogenous insulin levels in 
both opioid and nonopioid group as compared to control in cancer pain patients and the effect 
was independent of the glycemic status. These findings are inconsistent with earlier reports that 
high endogenous insulin level was observed in patients with pain in neck, shoulder and 
back(Elizabeth et al)37.The same fact was observed in another study wherein both opioid and 
nonopioid drugs caused a significant increase in endogenous insulin in patients with  cancer pain 
and the endogenous insulin was not associated with glycemic status(Nitya et al)17. 
                         The effect of circadian rhythm on the endogenous insulin in cancer pain patients 
receiving opioid or nonopioid analgesics was also examined. The cancer pain  patients who 
received who received  opioid group  showed a significant increase in endogenous insulin level  
in day cycle(6am and 12pm) whereas in nonopioid group showed significant increase in 
endogenous insulin  level in night cycle(6pm and 12’oclock midnight). 
                          On subjective analysis of cancer patients it was found, opioid group patients 
report more severity of pain in the day time than in the night time and therefore it is obvious 
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from our study, the changes in endogenous insulin level, high in day time an low in the night 
time.Besides,as a normal physiological function pancreas secrete  more insulin in daytime  and 
less in the night time in humans. These factors support our findings that circadian rhythm has a 
role to play in the endogenous insulin level relative to the intensity of pain. 
                             On comparison of insulin level between opioid and nonopioid groups there 
was about 2 fold increase in endogenous insulin level in nonopioid group and the mechanism 
underlying this is not clearly understood. Endogenous insulin has so far been implicated in the 
modulation of opioid mediate pain in the studies so far conducted and our finding with respect to 
two fold increase in insulin level in nonopioid group is surprising which need to be addressed in 
detail. 
                              We hypothesize the following factors may be reason for elevated endogenous 
insulin level in nonopioid group compared to opioid group. It has been stated that bradykinin 
stimulated insulin release (Chi yang et al)76. Bradykinin play a significant role in acute and 
chronic inflammatory pain.Bradykinin influences many biological processes such as blood 
pressure, local blood flow, pain and inflammation. Bradykinin activity is mediated by 2 
receptors, namely B1 and B2 receptors. The effects attributed to kinins are mainly mediated by 
B2 receptor which is expressed in many organs under physiological conditions. Conversely, 
B1receptor  is present only in low concentration in most tissues, but inflammation and pain 
triggers a strong up-regulation of B1 receptor expression in different organs(Molly A .Sevcik et 
al)79. Leptin is an adipocytokine that shows broad effects on energy balance, inflammation and 
vascular tone. Insulin is one of the major physiological and positive regulators of leptin 
expression and secretion in rodents and humans.B1 receptor is expressed in painful stimuli and 
this receptor causes leptin release which showed subsequent increase in insulin level.(Marcelo A 
Mori et al)75. 
                           Bradykinin showed insulin sensitivity via activation of B2 receptors whereas B1 
receptor may participate in this process through a cross walk with B2 receptor subtype addressed 
in a study(Leeb Lundberg LM et al)77.A study  reports that cytokines such as tumor necrosis 
factor α and interleukin -1 promote strong over expression of both leptin and kinin B1 receptor 
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mRNAs(Grunfeld C)78.Therefore it is strongly evident that pain causes release of cytokines and 
bradykinin.These two inturn results in βcell contraction causing an increase in insulin. 
                            Thus, the present study explores the possible role of endogenous insulin in 
cancer pain and also the circadian rhythm influences the endogenous insulin level in cancer pain 
patients particularly receiving opioid analgesics. Though cytokines and bradykinin may be 
contributing to endogenous insulin level in nonopioid group of patients a detailed study is 
warranted to clearly address this issue. 
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9.  SUMMARY AND CONCLUSION 
 
• VAS scale is an effective tool in assessing pain score in cancer pain. 
• Endogenous insulin is involved in the modulation of pain. 
• In painful condition like cancer pain, insulin possessed antinociceptive action with rise in 
endogenous insulin level independent of the glycemic status. 
• Circadian rhythm plays an important role on endogenous insulin in cancer pain. 
• Significant increase in insulin was observed in opioid group at the day cycle whereas in 
the nonopioid group the same effect was observed in the night cycle. This shows the 
influence of circadian rhythm over the insulin release. 
•  Thus, it can be concluded that endogenous insulin plays a role in the modulation of 
cancer pain treated by opioid and nonopioid analgesics and the circadian rhythm 
influences the relation  between endogenous insulin and cancer pain. 
• A detailed study in a larger population would help to understand the mechanism of 
endogenous insulin in clinical painful conditions and how they are affected by circadian 
rhythm.
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10. FUTURE PLAN 
 
        Further studies are required in more number of subjects to confirm the influence of 
circadian rhythm on insulin level and glycemic status in cancer pain patients.
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DATA ENTRY FORM 
 
PATIENT DETAILS 
NAME:                                                                                      AGE: 
SEX:                                                                                           BMI : 
  
PAST  MEDICATION HISTORY: 
FAMILY  HISTORY: 
SOCIAL HISTORY:  
  
SMOKER(Y/N) :                                                                    ALCOHILIC(Y/N): 
 
REASON FOR ADMISSION: 
 
TYPE  OF CANCE:   
STAGE OF CANCER : 
HISTO PATHOLOGICAL DETAILS: 
INVESTIGATION : 
 
CHEMOTHERAPY 
 
DRUG : 
DOSE: 
ROUTE : 
HOW MANY CYCLE COMPLETED :
YET TO BE COMPLETED : 
TRETMENT OUTCOME: 
PAIN SCORE : 
 
LABORATORY INVESTIGATION 
 
SERUM  INSULIN LEVEL: 
 
BLOOD GLUCOSE LEVEL:
SWAMY VIVEKANANDHA COLLEGE OF PHARMACY 
Elayampalayam, Tiruchengode-637 205, Tamilnadu. 
 
PATIENT INFORMATION FORM 
STUDY TITLE: 
Chronological effect on insulin level and glycemic status in cancer pain patients 
 
STUDY SITE: 
Erode Cancer centre, Erode 
 
DESCRIPTION: 
This study conducted by NEENU B NIRAVATH [II M.Pharm (Pharmacy Practice), Swamy Vivekanandha College of 
Pharmacy ,Elayampalayam Thiruchengode-637 205, Tamilnadu.] will help in understanding the insulin level in cancer 
patients, and the importance of monitoring insulin and glucose level in patients with cancer for better therapeutic 
outcome. 
PARAMETERS TO BE MEASURED: 
 
¾ Insulin level 
¾ Glucose level 
 
AMOUNT OF BLOOD NEEDED: 5ml 
 
All the volunteers willing to participate in this research study are requested to sign in the patient consent form.
Swamy Vivekanandha College of Pharmacy 
Elayampalayam, Thiruchengode-637 205, Tamilnadu 
 
CONSENT FORM 
 
I Mr/Mrs/Miss........................................... patient of Dr. K.VELAVAN.MD.   RT.,   Consultant Radiation 
Oncologist & Cancer Chemotherapist, Erode Cancer Centre  ,Erode, hereby declare that I have been told 
in detail by NEENU B NIRAVATH [II M.Pharm (Pharmacy Practice),Swamy Vivekanandha College of 
Pharmacy,Elayampalayam]about the study titled, “CHRONOLOGICAL EFFECT ON INSULIN LEVEL 
AND GLYCEMIC STATUS IN CANCER PAIN PATIENTS”. I have understood completely and I agree to 
take part in this research and to donate venous blood samples which will help in acquiring knowledge for 
the benefit of the mankind. 
 
                                      
                                                                                      
                                                                                       Signature/thumb impression of Patient 
 
 
Signature of Pharmacist                                                                                                  Signature of Physician  
Date:  
